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Tuberculosis (TB) is a recurring threat to contemporary civilization. It affects not only those within devel-
oping countries, but has also appeared again in places where it was once considered eradicated. TB co-
infection in patients infected by HIV is, at the time of writing, the most common cause of death. In the field
of searching for new antimycobacterial drug leads, compounds of natural origin still remain a promising
source. The review is intended to gather information about natural products (metabolites of plants, fungi,
bacteria, and marine sponges) that show activity against mycobacterial enzymes. Here, natural metabolites
are presented as being inhibitors/activators of the mycobacterial enzymes involved in mycobacterial growth
in vitro (ClpC1, ClpP, MurE ligase, mycothiol S-conjugate amidase, b-ketoacyl-ACP synthase, InhA) and
in vivo, as regards the host cell (PtpB). Each enzyme is briefly described so as to generate an understanding
of its role in mycobacterial growth and engender a perception of the mechanism of action of the studied
natural compounds. Furthermore, after the introduction of the enzyme, its inhibitors are listed and exactly
characterized.Introduction
Tuberculosis (TB) is still an undefeated disease, due to the emer-
gence of resistant strains causing multidrug-resistant (MDR-TB:
resistant to isoniazid and rifampicin) and extensively drug-resis-
tant tuberculosis with additional resistance to fluoroquinolones
and injectable drugs (XDR-TB: amikacin, kanamycin, capreomy-
cin). Themain reason for the development of suchmycobacterial
resistance is patient non-adherence to treatment, as well as the
adverse side effects of conventional anti-TB drugs (WHO, 2014).
TB remains the most common cause of death among patients
with AIDS, leading to the deaths of one in every three patients
(Zwang et al., 2007). In HIV infection, defective macrophage
function is a demonstrated response to TB infection, which
may, in part, increase susceptibility to TB disease (Patel et al.,
2009).
Mycobacterium tuberculosis is a unique pathogen because of
its slow growth, dormancy, complex cell envelope, intracellular
pathogenesis, and genetic homogeneity (Cole et al., 1998). The
bacteria needs 24 hr for reproduction in synthetic medium or
infected animals. This contributes to the chronic nature of the
disease, and imposes lengthy treatment regimens. The state of
dormancy is a bacterial metabolic shutdown induced by a host
cell-mediated immune response that can restrain, but not erad-
icate, the infection (Cole et al., 1998). The cell envelope of
M. tuberculosis contains peptidoglycan (highly enriched in un-
usual lipids, glycolipids, and polysaccharides) and an additional
layer composed of mycolic acids, mycocerosic acid, phenolthio-
cerol, lipoarabinomannan, and arabinogalactan. Several compo-
nents of this additional layer may contribute to mycobacterial
longevity, trigger inflammatory host reactions, and act in patho-
genesis (Cole et al., 1998). These characteristic features of
M. tuberculosis cell biology make it different to other pathogenic
bacteria, and emphasize the need for investigating compounds
that act selectively on targets occurring only in these bacteria.
Worldwide, vast efforts have been undertaken to discover
potent and safe drugs with new mechanisms of action, killing1288 Chemistry & Biology 22, October 22, 2015 ª2015 Elsevier Ltd Anot only actively growing but also latent M. tuberculosis
H37Rv. At present, according to the Working Group on New
TB Drugs (2015), several drug candidates are in clinical develop-
ment. These are nitroimidazole (TBA-354 in the first phase), ox-
azolidones (AZD5847 and PNU-100480 in the second phase),
ethylenediamine (SQ109 in the second phase), diarylquinoline
(bedaquiline with accelerated approval of the Food and Drug
Administration in the fourth phase) and nitro-dihydro-imidazoox-
azole (delamanid in the third phase).
These potential drugs have been mainly discovered via large-
scale screening of synthetic compound libraries. However,
natural product-based TB drugs are still vital components of
first- and second-line usage in TB treatment. During the last
two decades, many natural products have been reported to
have activity against mycobacteria, and thus are the target of a
number of recent comprehensive reviews of anti-Mycobacte-
rium natural products (Garcı´a et al., 2012; Gautam et al., 2007;
Newton et al., 2002; Okunade et al., 2004; Pauli et al., 2005;
Salomon and Schmidt, 2012). The particular natural products
targeting mycobacterial enzymes mentioned in this review can
also be described as being promising drug leads.
The Sources of Anti-TB Natural Product Drug Leads
Besides the synthetic organic compounds used in TB treatment,
several antibiotics used in TB therapy are derived from microor-
ganisms, as the secondary metabolites produced by one bacte-
ria strain may either kill or inhibit the growth of another bacteria.
The intensive search for antibiotics from soil microorganisms
began in the mid-20th century, and has yielded several clinically
useful TB drugs (Gao et al., 2015). Such recently discovered and
rediscovered compounds targeting mycobacterial enzymes are
certain soil bacteria metabolites, among which are acyldepsi-
peptides, cyclomarin A, ecumicin, lassomycin, pyridomycin,
and thiolactomycin. Aside from the aforementioned soil bacteria,
which are considered to be valuable sources of natural products,
cyanobacteria, as well as marine sponges, have been describedll rights reserved
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against mycobacterial enzymes (Mu¨ller et al., 2006; Nicholas
et al., 2001).
Mycobacterial Enzymes as Ideal Targets
The selective toxicity of antibiotics is based on finding vulnerable
drug targets in the invasive microbe which do not exist in the hu-
manhostbody that isgiven thedrug.Mostantibiotics inclinical us-
agearedirectedagainstbacterial cellwall synthesis, bacterial pro-
tein synthesis, or bacterial nucleic acid synthesis that are unique in
some ways to particular bacteria (Adrien, 2006). All of these tar-
gets are proteins with enzymatic activity. The ideal drug target
is, hence, an enzyme with fully elucidated function and mecha-
nism, and which is absolutely required for the survival of the
microbe (Brown and Wright, 2005; Salomon and Schmidt, 2012).
Sassetti and Rubin (2003) have identified 194 genes that are
specifically required for mycobacterial growth in vivo. They
noted that a large fraction of these genes are unique to myco-
bacteria and closely related species. Furthermore, the distribu-
tion of functions for the genes necessary for in vivo growth was
found to be different from those previously defined as important
for growth on agar medium.
An essential challenge in antibacterial drug discovery is
demonstrating beyond any doubt that compounds with in vitro
enzyme activity possess the desired antibacterial effect by inter-
fering with the same target in whole bacterial cells. This effect
can be estimated within investigated compounds by profiling
cellular biomarkers in whole bacterial cells or in animals using
compounds that are known inhibitors or activators of a particular
target (Greis et al., 2005).
This review presents an overview of the natural products
targeting a variety of mycobacterial enzymes. The essence of
each enzyme’s activity and its characteristic are put forth to
promote the understanding of the mechanism of action of the
investigated secondary metabolites isolated from bacteria, ma-
rine sponges, and plants.
Caseinolytic Protease
Bacterial caseinolytic proteases (Clps) are important for protein
turnover and homeostasis to maintain vital cellular functions,
particularly under stress conditions. Apart from their crucial
role in general protein quality control brought about by degrading
abnormally folded or otherwise aberrant or malfunctioning pro-
teins, their temporally and spatially precise proteolysis of key
regulatory proteins (such as transcription factors) additionally
guides several developmental processes. Among these are cell
motility, genetic competence, cell differentiation, sporulation,
and important aspects of virulence (Raju et al., 2012; Sassetti
et al., 2003). Furthermore, in some actinomycetales, including
M. tuberculosis, ClpP is even essential for growth in vitro, since
the gene can only be deleted from the chromosome when a sec-
ond functional copy is provided (Ollinger et al., 2012).
For proteolytic activity, ClpP strictly depends on correspond-
ing Clp-ATPases (ClpC1). ClpC1 belongs to the group of
ATPases associated with various cellular activities. The ClpC1
proteins function as regulatory subunits of the Clp. This is,
hence, a chaperone that unfolds protein substrates in an ATP-
dependent manner before channeling them to the ClpP protease
subunit of the complex.Chemistry & BiologThe Clp complex typically consists of a sandwich of two hep-
tameric rings of ClpP protease units flanked by two hexameric
rings of Clp-ATPases. Thus, structurally and functionally, it re-
sembles the eukaryotic proteasome. Clp-ATPases bind protein
substrates in the cytoplasm and transport them to ClpP. Here,
the Clp-ATPases unfold their substrates and translocate them
through the axial pores into the ClpP proteolytic chamber using
energy derived from ATP hydrolysis. For the interaction with the
ClpP tetradecamer, the Clp-ATPases form hexamers that stack
to the apical and/or distal surface of the ClpP barrel (Kim and
Kim, 2003).
Mycobacteria, including M. tuberculosis and Mycobacterium
smegmatis, unlike most well-studied prokaryotes, have two
homologs of the ClpP proteolytic core (ClpP1, ClpP2) and three
potential Clp-ATPases (ClpC1, ClpC2, ClpX) (Raju et al., 2012).
Raju et al. (2012) demonstrated that these two proteins form a
mixed complex (ClpP1P2) in mycobacteria. Using two different
approaches leading to the inducible expression of ClpP1 and
ClpP2, promoter replacement, and a novel system of inducible
protein degradation, they revealed that both genes are essential
for growth and that a marked depletion of either one results in
rapid bacterial death. ClpP1 and ClpP2 assemble to form a sin-
gle proteolytic complex, referred to as ClpP1P2, and each sub-
unit is absolutely required for proteolysis, for normal growth of
M. tuberculosis in vitro and during the demonstrated infection
of mice (Raju et al., 2012). Pure ClpP1 and ClpP2 by themselves
form tetradecamers, which are inactive. However, in the pres-
ence of low molecular weight activators they reassociate to
form amixed tetradecamer, ClpP1P2, which is capable of prote-
olysis (Akopian et al., 2012; Raju et al., 2012).
ClpP1P2 appears important in degrading missense and
prematurely terminated peptides, as a partial depletion of
ClpP2 reduces growth, specifically in the presence of antibiotics
that increase errors in translation. Thus, in the absence of
ClpP1P2-mediated proteolysis, protein synthesis might eventu-
ally be inhibited, causing cell death. The unusual properties of
this complex, the absence of such an enzyme in the eukaryotic
cytoplasm, and the essentiality of both subunits, make ClpP1P2
an attractive target for novel therapeutic development for the
treatment of tuberculosis (Ollinger et al., 2012; Raju et al., 2012).
Acyldepsipeptides (ADEPs) (Figure 1) were the first antibi-
otics selectively targeting ClpP. A group of eight closely related
ADEPs was isolated from the fermentation broth of Strepto-
coccus hawaiiensis NRRL 15010, and briefly described as the
‘‘A54556 complex’’ in a patent (Michel and Kastner, 1985).
Bro¨tz-Oesterhelt et al., (2005) found that immobilized ADEP
retained ClpP during affinity chromatography. The characteriza-
tion of ADEP-resistant mutants revealed mutations in the ClpP
gene, confirming ClpP as a target (Bro¨tz-Oesterhelt et al., 2005).
ADEP1 is a natural 16-membered peptidolactone consisting
of five L-amino acids, to which a lipophilic polyene side chain
is appended. The stability and antibacterial activity of these eno-
peptins was further enhanced by synthetic modifications
yielding other ADEP compounds. The minimum inhibitory con-
centration (MIC) values determined for modified ADEP2,
ADEP3, and ADEP4 on the M. tuberculosis were 31, 125, and
65 mM, respectively (Ollinger et al., 2012).
In-depth structural and biochemical analyses on the interac-
tion of ADEPs with ClpP revealed that ADEPs deregulate ClpPy 22, October 22, 2015 ª2015 Elsevier Ltd All rights reserved 1289
Figure 1. Compounds Targeting Clp
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studies using purified ClpP showed that in the absence of ClpP-
ATPases, ADEPs induce the oligomerization of ClpP monomers
into the tetradecameric complex, which, however, is no longer
functional in the physiological sense.
By way of further study, it emerged that ADEPs prevent the
interaction of ClpP with its Clp-ATPases and, thus, inhibit the
degradation of natural Clp protease substrates (Kirstein et al.,
2009). Moreover, preformed ClpP/Clp-ATPase complexes
were even disassembled in the presence of ADEP (Kirstein
et al., 2009). It turns out that ADEPs uncouple the proteolytic ca-1290 Chemistry & Biology 22, October 22, 2015 ª2015 Elsevier Ltd Apacity of ClpP from its natural regulatory constraints, thereby
switching ClpP from a regulated to an uncontrolled protease
that degrades fully or partly unfolded or flexible proteins such
as casein, aswell as nascent polypeptides at the ribosome, inde-
pendently of Clp-ATPases (Bro¨tz-Oesterhelt et al., 2005; Kirstein
et al., 2009). Furthermore, ADEP activity was enhanced by the
addition of efflux pump inhibitors, demonstrating that ADEPs
gain access to the cell, but that export occurs (Ollinger et al.,
2012).
The ADEP series of compounds have an unusual mode of ac-
tion, since they do not inhibit a cellular function but activate all rights reserved
Figure 2. Schematic Description of Mode of Action of Caseinolytic
Protease Inhibitors
(A) In normal conditions Clp-ATPases support the oligomerization of ClpP into
the tetradecameric complex, bind the protein substrates, unfold them, and
translocate them through the apical and/or distal entrance pores into the
proteolytic chamber of ClpP for substrate proteolysis. The N-terminal domain
of ClpC regulates access to the tunnel made by ClpC ATPase domains and the
associated Clp protease machinery. The ATPase domains are involved in the
ATP-dependent unfolding of the proteins for proteolysis by ClpP.
(B) ADEPs interact with the same binding site as Clp-ATPases on the ClpP.
ADEP binding to the N terminus of ClpP widens the ClpP opening, preventing
the binding to the regulatory ATPase and leading to uncontrolled proteolysis of
essential nascent peptides and proteins.
(C) Cyclomarin A binds to N-terminal domain of ClpC1 and reduces the flexi-
bility of the linker between the two N-terminal repeats, making them immobile
and leaving the ClpC1 tunnel open. This could allow free access for larger
proteins into the unfolding and proteolytic core of the Clp machinery. This can
lead to cell death if functional or partially folded nascent proteins are
degraded.
(D) Ecumicin and lassomycin stimulate ATPase activity but block ClpC1-
mediated protein breakdown by ClpP. They uncouple ATP hydrolysis from
proteolysis. CertainM. tuberculosis proteins that are normally degraded by the
ClpC1 complex are highly toxic and accumulate in the presence of ecumicin
and lassomycin.
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cells. This explains why ADEPs are active against organisms
in which ClpP is not an essential protein; in such species,
ADEP resistance results from the deletion of ClpP. However, in
M. tuberculosis, ClpP is essential, so that deletionmutantswouldChemistry & Biolognot be viable; this could be advantageous in that resistance to
ADEPs may be more difficult to acquire (Ollinger et al., 2012).
The profiling of cellular biomarkers of enzyme activity in whole
bacterial cells or in animals was not performed.
Another natural antibiotic, cyclomarin A (Figure 1), was iso-
lated from Streptomyces sp. This cyclopeptide was identified
to be bactericidal against a panel of MDR clinical isolates of
M. tuberculosis, at concentrations of 0.3–2.5 mM, in a natural
product whole-cell screen (Schmitt et al., 2011). Cyclomarin A
was found to be active against growing, as well as hypoxic
non-replicating M. tuberculosis cells; however, it lacked activity
against other tested Gram-positive or Gram-negative species,
includingStaphylococcus aureus andPseudomonas aeruginosa.
In work carried out by Schmitt et al. (2011), an affinity chroma-
tography approach using an immobilized derivative of cyclo-
marin A selectively trapped the mycobacterial ATPase ClpC1,
while further experiments showed that cyclomarin interact
with ClpC1 with high affinity in a 1:1 stoichiometry. Further
work also demonstrated that cyclomarin specifically increases
proteolysis mediated by the Clp inside the cell.
The enzyme activity was linked to the whole-cell activity in the
undertaken whole-cell fluorescence-based protein degradation
assays. In these experiments, cyclomarin reduced the amount
of captured protein by 50% at a concentration of 10 nM, thus
suggesting a specific and high-affinity binding to the N-terminal
domain of ClpC1 (Figure 2), and no interference with ATP binding
by the two ATPase domains of ClpC1 (Schmitt et al., 2011).
Beyond the aforementioned, it was ascertained that structural
changes in the hexameric ClpC1 ring upon the binding of cyclo-
marin led to functional changes of the protein complex and an
increased proteolytic activity of the ClpP/ClpC1 complex in
mycobacterial cells. By this means, cyclomarin displayed effec-
tive killing of M. tuberculosis growing in culture broth as well as
in macrophages (Schmitt et al., 2011). The profiling of cellular
biomarkers of enzyme activity in animals was not performed
for this compound.
Lassomycin (Figure 1), which was purified by Gavrish et al.
(2014) from an extract of soil bacteria, Lentzea kentuckyensis
sp. is a highly basic, ribosomally encoded cyclic peptide with
an unusual structural fold that only partially resembles that of
other lasso peptides. It has high activity against both growing
and dormant mycobacteria, including drug-resistant, MDR,
and extremely drug-resistant isolates of M. tuberculosis (MIC
in the range of 0.42–1.57 mM), but little activity against other bac-
teria or mammalian cells. Furthermore, the killing activity against
stationaryM. tuberculosiswas greater than rifampicin without an
obvious presence of surviving persisters (Gavrish et al., 2014). In
addition, the compound brings about no lysis of erythrocytes
and has low cytotoxicity (half-maximal inhibitory concentration
[IC50] 184 mM) against NIH 3T3 and HepG2 cells, perhaps due
to poor penetration into mammalian cells (Gavrish et al., 2014).
Lassomycin, even at low concentrations, enters
M. tuberculosis and binds to an acidic N-terminal pocket on
ClpC1 ATPase. Gavrish et al., (2014) described that in the pres-
ence of low concentrations of lassomycin, ATP hydrolysis by
ClpC1 increased up to 7- to 10-fold. This antibiotic markedly
stimulates ATPase activity without stimulating ClpP1P2-cata-
lyzed protein breakdown (Figure 2). Moreover, in the presence
of lassomycin, ClpC1 seems to bind protein substrates normally,y 22, October 22, 2015 ª2015 Elsevier Ltd All rights reserved 1291
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compartment (Gavrish et al., 2014). This mechanism, uncoupling
ATPase from proteolytic activity, accounts for the bactericidal
activity of lassomycin. Most likely, the conformational changes
induced by lassomycin interfere with ClpC1’s association with
ClpP1P2 (Gavrish et al., 2014). As with the previously mentioned
compounds, the profiling of cellular biomarkers of enzyme activ-
ity in whole bacterial cells or in animals was not performed.
High-throughput screening of actinomycete extracts have
yielded a macrocyclic tridecapeptide, ecumicin (Figure 1), which
exerts potent bactericidal activity againstM. tuberculosis in vitro
(minimal bactericidal concentration of 0.34 mM), including non-
replicating cells (Gao et al., 2015). Ecumicin, which was isolated
from Nonomuraea species strain MJM5123, is active against
isolated MDR and XDR strains ofM. tuberculosis, but has no ac-
tivity against S. aureus, Escherichia coli, or Candida albicans, at
32 mM. This suggests its selectivity (Gao et al., 2015). Further-
more, the demonstrated activity against mycobacterial strains
resistant to streptomycin and rifampicin indicates a different
molecular target to that of these drugs. Moreover, ecumicin is
selective with respect to mammalian cells, revealing a selectivity
index of 640 (Gao et al., 2015).
Ecumicin acting in vivo was shown to inhibit the growth of
M. tuberculosis in the lungs of mice. The undertaken work
also demonstrated that the ClpC1 ATPase complex is its target.
Ecumicin uncouples ClpC1-mediated ATP hydrolysis from
ClpP1P2 proteolysis (Figure 2). It markedly and specifically en-
hances the M. tuberculosis ATPase activity, but prevents the
activation of proteolysis by ClpC1, and does not affect the ac-
tivity of a variety of purified bacterial ATPases. This specificity
and the fact that ClpC1 is essential only in mycobacteria can
account for ecumicin’s selective toxicity. Furthermore, ecumi-
cin has been shown to have poor to modest intestinal absorp-
tion, and remains substantially unchanged by human or mouse
liver microsomes. In addition, encapsulated in micelles it can
be distributed to mouse lung tissue and accumulate there,
thus having potent bactericidal activity within host cells (Gao
et al., 2015). Of note, the profiling of cellular biomarkers of
enzyme activity in whole bacterial cells or in animals was not
performed.
Comparison of compounds interacting with Clp is shown in
Table 1.
The other interesting cyclic peptides revealing anti-tubercular
activity, lariatins A (‘‘lasso’’ structure) and B, were isolated from
Rhodococcus jostii K01-B0171, and showed selective and
strong inhibition against tested mycobacterium species. The
MIC values determined against M. smegmatis were 1.52 and
2.79 mM for lariatins A and B, respectively. Furthermore, lariatin
A was shown to inhibit the growth of M. tuberculosis, revealing
a MIC of 0.19 mM (Iwatsuki et al., 2006, 2007).
Beyond the aforementioned, a cyclic peptide antibiotic, dihy-
dromycoplanecin A (DHMP A), demonstrated stronger activities
than standard antimycobacterial drugs. In undertaken studies,
MICs for 90% of isolates of mycobacteria were 0.042 mM
for M. tuberculosis, 0.66 mM for Mycobacterium kansasii, and
21 mM for Mycobacterium intracellulare. It was also active
againstMycobacterium bovis. This peptide was evaluated in vivo
in mice infected with M. tuberculosis H37Rv. In this work, a sig-
nificant decrease in the number of bacteria was observed in the1292 Chemistry & Biology 22, October 22, 2015 ª2015 Elsevier Ltd Aspleens of animals that received DHMP A, but not in the lungs
(Haneishi et al., 1988).
The cyclic peptides, wollamides A and B, which were isolated
from a soil Streptomyces sp. nov. (MST-115088), have also
exhibited antimycobacterial activity (MIC = 2.8 and 3.1 mM,
respectively), including reduction in the intracellular mycobacte-
rial survival in murine bone marrow-derived macrophages.
These compounds were demonstrated to be non-cytotoxic to
mammalian cells (Khalil et al., 2014). Regarding all of the afore-
mentioned, none of the compounds in this group was studied
for their enzyme inhibitory activity.
ATP-Dependent MurE Ligase
The ATP-dependent MurE ligase of M. tuberculosis is a
requirement in the biosynthesis of peptidoglycan. The enzymes
involved in the peptidoglycan biosynthetic pathway are charac-
teristic of eubacteria and are absent in humans. These enzymes
are, therefore, excellent targets for anti-infective drug develop-
ment (Osman et al., 2012). The peptidoglycan layer of the cell
wall serves as a base for the lipid-rich capsule. Moreover, pepti-
doglycan (or murein) is the polymeric mesh of the bacterial cell
wall that plays a vitally important role in protecting bacteria
against osmotic lysis.
Peptidoglycan biosynthesis can be separated into two
phases, comprising six intracellular enzymatic steps and three
steps that occur outside of the plasma membrane (Turk et al.,
2009). Most antimicrobials target steps are in the later stage
of cell wall biosynthesis; however, the earlier steps in peptido-
glycan biosynthesis have recently received renewed attention
in terms of novel therapeutic targets (Spiegelman, 2007). Among
the cytoplasmic steps involved in the biosynthesis of peptido-
glycan, four ATP-dependent ligases (MurC, MurD, MurE, and
MurF) catalyze the assembly of its peptide moiety by successive
additions of L-alanine, D-glutamate, a diamino acid (usually
meso-diaminopimelic acid [m-DAP] or L-lysine) and D-alanyl-
D-alanine to UDPN-acetylmuramic acid (MurNAc). The gene en-
coding ATP-dependent MurE ligase occurs as a single copy in
the M. tuberculosis genome, and was found to be essential for
bacterial growth and survival (Basavannacharya et al., 2010).
Among several natural products screened for inhibitory
activity against MurE M. tuberculosis ligase, Guzman et al.
(2010) found the aporphine alkaloids (Figure 3), 3-methoxynor-
domesticine, N-methoxycarbonyl-3-methoxynordomesticine,
and 3-methoxynordomesticine hydrochloride, to be very potent
selective inhibitors of slow-growing mycobacteria (Guzman
et al., 2010). In their study the growth inhibition against
M. tuberculosis H37Rv in a liquid medium and M. bovis BCG in
both solid and liquid media were assessed for these com-
pounds. Interestingly, the result of such work demonstrated
that the anti-tubercular activity was more pronounced for the
polar and mildly acidic alkaloid 3-methoxynordomesticine
hydrochloride (MIC %14 mM), when compared with the more
basic compound 3-methoxynordomesticine (MICR73 mM) and
N-methoxycarbonyl-3-methoxynordomesticine (MICR125 mM)
(Guzman et al., 2010). Furthermore, the same study also assayed
overexpressed and purified recombinant M. tuberculosis
protein MurE under different concentrations of natural
products, using the colorimetric detection of phosphate. This
compound has been shown to be stoichiometrically coupled toll rights reserved
Table 1. Comparison of Compounds Interacting with Clp
Compound
Ribosomal
versus NRPs
Coding MW
Natural
versus
Modified MIC (mM) Spectrum of Activity Pk Parameters In Vivo Efficacy
Effect on
Protein
Degradation Reference
ADEP 1 NRPs coding 719 natural – good activity against
Gram-positive bacteria,
but not against
Gram-negative bacteria
chemical lability and poor
solubility
limited efficacy
in vivo
enhance Clardy et al., 2006;
Conlon et al., 2012
ADEP 4 – 769 modified 65 for M. tuberculosis Enterococcus faecalis;
Staphylococcus ureus,
M. tuberculosis
achievable concentration in
animals is 9.75 mM
good in several
animal models
enhance Socha et al., 2010
Cyclomarin A NRPs coding 1,043 natural 0.3 for M. tuberculosis
2.5 for M. smegmatis
0.3 for M. bovis
good activity against a
panel of multidrug-resistant
clinical isolates of
M. tuberculosis, but not
against other tested
Gram-positive or
Gram-negative bacteria
lacks good pharmacokinetic
properties
not tested enhance Schmitt et al., 2011;
Schultz et al., 2010;
Srinivasa et al., 2013
Lassomycin Ribosomal
coding
1,901 natural 0.42–1.57 for different
mycobacterial strains
little activity against other
bacteria
no data not tested retard Gavrish et al., 2014
Ecumicin NRPs coding 1,599 natural 0.34 for M. tuberculosis active against isolated MDR and
XDR strains of M. tuberculosis,
but have no activity against
S. aureus, Escherichia coli, or
Candida albicans
poor to modest intestinal
absorption; remains
unchanged by human or
mouse liver microsomes;
in the micelle formulation
accumulates in mouse
lung tissue
active in mouse
model of acute
TB infection,
retard Gao et al., 2014;
Gao et al., 2015
NRPs, non-ribosomal peptides; MW, molecular weight; Pk, pharmacokinetic.
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Figure 3. Outer Membrane Inhibitors and Compounds Targeting PtpB and MCA
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Figure 4. The Schematic Mode of Action of
Outer Membrane Inhibitors
Mur E ligase is one of four ATP-dependent ligases
which catalyze the assembly of its peptide moiety
to UDP N-acetylmuramic acid. The action of
aporphine alkaloids disrupts the peptidoglycan
formation. b-Ketoacyl-ACP synthase and NADH-
dependent enoyl-ACP reductase InhA are involved
in the FAS-II system, which extends fatty acids
for the synthesis of very long-chain mycolic acids.
Inhibition of FAS-II system enzymes by pyr-
idomycin and thiolactomycin results in decreased
or inhibited formation of mycolic acid. LAM, lip-
oarabinomannan.
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2010). The results of such work revealed that the aporphine alka-
loids were found to be inhibitory to M. tuberculosis ATP-depen-
dent MurE ligase (Figure 4) at micromolar concentrations (IC50
values from 57 to 75 mM) (Guzman et al., 2010). In this experi-
ment, the profiling of cellular biomarkers of enzyme activity in
whole bacterial cells or in animals was not performed.
Protein Tyrosine Phosphatase B Inhibitors
Protein tyrosine phosphatases (Ptps) are a group of enzymes
that remove phosphate groups from phosphorylated tyrosine
residues on proteins. This protein tyrosine phosphorylation is
a common post-translational modification important for protein
interactions and cellular localization. Moreover, it has an effect
upon protein stability and the regulation of enzyme activity.
Beyond the aforementioned, Ptps are also involved in signaling
and the control of cell cycle, cell growth, proliferation, differenti-
ation, and transformation (Paul and Lombroso, 2003). Protein
tyrosine phosphatases A (PtpA) and B (PtpB) are produced
and secreted into the host cell by M. tuberculosis, and they
attenuate host immune defenses by interfering with the host
signaling pathways and shutting down critical cellular pro-
cesses, thus promotingM. tuberculosis survival among themac-
rophages (DeVinney et al., 2000). Thereby, PtpA and PtpB inhibi-
tion by small molecules could negatively affect M. tuberculosis
survival in the host. Indeed, in vivo studies performed with acti-
vated macrophages of guinea pigs have shown that gene inacti-
vation of PtpB had provoked accelerated mycobacterial cell
death after macrophage invasion (Singh et al., 2003).
More recently, Zhou et al., (2010) proposed that PtpB pro-
motes mycobacterial survival in cultures of macrophages by in-
hibiting extracellular signal-regulated kinase 1/2 (ERK1/2) and
p38 pathways, and by increasing the phosphorylation of Akt,
resulting in reduced production of interleukin-6 and decreased
apoptotic activity, respectively.
Molecular docking, rescoring, and visual inspection was used
by Mascarello et al. (2013) to prioritize several natural com-
pounds as possible PtpB inhibitors. Based on the in silico calcu-
lations, 14 compounds were selected for biological investiga-
tions in vitro. Subsequently, in the phosphatase assays which
were carried out on the purified enzyme, similarly as previously
described (Chiaradia et al., 2012), six compounds showed signif-Chemistry & Biology 22, October 22, 2015 ªicant inhibition of PtpB. Among these, Ku-
wanol E (Figure 3), a polyhydroxylated Di-
els-Alder type adduct metabolite isolatedfrom Morus nigra cell cultures, was the most potent (IC50 =
1.9 mM). Follow-up kinetic analysis has revealed that Kuwanol
E acts as a PtpB competitive inhibitor (Figure 5). Indeed, peptide
mass fingerprint analyses performed by mass spectrometry
showed that Kuwanol E was able to protect the PtpB catalytic
site against the proteolytic activity of trypsin, thus reinforcing
the proposed notion that this inhibitor may interact within the
PtpB catalytic site. Mascarello et al. (2013) opine that the
possible binding mode of KuwE with PtpB, investigated by mo-
lecular docking, is via hydroxyl groups of KuwE performing
H-bond interactions with the catalytic site of PtpB. TheMIC value
of the investigated compound was, however, not assessed.
Furthermore, the profiling of cellular biomarkers of enzyme activ-
ity in whole bacterial cells or in animals was not undertaken.
Mu¨ller et al. (2006) isolated cyclic hexapeptides from the
cyanobacterium Tychonema sp. These showed inhibitory activ-
ity against PtpB (Figure 5) from M. tuberculosis. The in vitro
enzymatic assay toward PtpB was performed spectrophotomet-
rically, on the purified enzyme as previously described (Seibert
et al., 2006), with the obtained values being in the lower micro-
molar range. The data derived from the work showed that the
enzyme was potently inhibited by brunsvicamide B (IC50 =
7.3 mM) and brunsvicamide C (Figure 3) (IC50 = 8.0 mM). Further-
more, these peptides do not interact with other tested, non-
mycobacterial phosphatases, and hence have high selectivity
toward the Mycobacterium-derived enzyme (Mu¨ller et al.,
2006). However, the MIC value of the investigated compounds
and the molecular interactions with the enzyme were not as-
sessed. In addition, profiling of cellular biomarkers of enzyme
activity in whole bacterial cells or in animals was not performed.
Mycothiol S-Conjugate Amidase
Mycothiol S-conjugate amidase (MCA) is mycobacterial detoxi-
fication enzyme. It was first isolated from M. smegmatis, and is
involved in neutralizing a variety of alkylating agents and xenobi-
otics. Among these are formaldehyde, nitric oxide, and certain
antibiotics (Steffek et al., 2003). MCA hydrolyzes the cysteinyl-
glucosamine amide bond of the mycothiol S-conjugate,
releasing the AcCys S-conjugate (a mercapturic acid), which
can be excreted into themedium, as well as the GlcN-Insmoiety,
which is retained in the cell and used for the regeneration of my-
cothiol. Mycothiol is the primary low molecular weight thiol in2015 Elsevier Ltd All rights reserved 1295
Figure 5. Schematic of the Mode of Action of PtpB Inhibitors
Protein tyrosine phosphatase B (PtpB) is produced and secreted into the host
cell by M. tuberculosis (indicated as red arrows) and attenuates host immune
defenses by interfering with the host signaling pathways.
(A) PtpB activity leads to decreased phosphorylation of extracellular signal-
regulated kinase 1/2 (ERK1/2) and p38 (blue arrows), and increased
phosphorylation of Akt (green arrows), resulting in reduced production of
interleukin-6 (IL-6) (blue arrows) and decreased apoptotic activity, respec-
tively. Intensifying or shutting down critical cellular processes promotes
M. tuberculosis survival among the macrophages.
(B) The PtpB inhibitors Kuwanol E and brunsvicamides alleviate the effects of
an enzyme (red cross mark) and increase the ability of host immune defenses
and eradication of M. tuberculosis.
Figure 6. Schematic of the Mode of Action of MCA Inhibitors
(A) To neutralize the xenobiotic (red triangles), it is coupled within the cell with
a molecule of mycothiol (MSH). Mycothiol S-conjugate amidase (MCA) hydro-
lyzes the cysteinyl-glucosamine amide bond of the xenobiotic mycothiol
S-conjugate (MSR) (green triangles), releasing the AcCys S-conjugate (a mer-
capturic acid), which can be excreted into the medium, as well as the GlcN-Ins
moiety, which is retained in the cell and used for the regeneration of mycothiol.
(B) The inhibition of MCA (magenta arrow and cross mark) by bromotyrosine-
derived natural products leads to accumulation of toxins (green trinagles) in-
side the cell and, subsequently, cell death.
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mycobacteria (Newton et al., 1996). Like glutathione, mycothiol
is maintained in a reduced state by mycothiol disulfide reduc-
tase. Moreover, it appears to play a key role in protecting the
cell against oxidative stress and challenge by electrophilic
toxins. Mycothiol and MCA are not found in glutathione-produc-
ing mammals and hence, drugs inhibitingMCAmay be less toxic
than those for other drug targets (Steffek et al., 2003).
Nicholas et al. (2001) were the first to describe in the literature
both novel and known bromotyrosine-derived natural products
(Figure 3) isolated from an Australian non-verongid sponge,
Oceanapia sp. They noted these as being inhibitors of a myco-
bacterial MCA, with IC50s being in the low micromolar range. In
follow-upwork, Nicholas et al. (2003) used a fluorescence detec-
tion assay to assess the degree of inhibition of MCA activity on
the substrate mycothiol bimane (MsmB), so as to screen natural
product extracts (mainly from marine plants and terrestrial fungi)
to find suitable MCA inhibitors. In this study they found three
types of bromotyrosine-derived natural products inhibiting
MCA at micromolar concentrations. Among these were com-
pounds containing a spirocyclic isoxazoline ring system
(including spiro[4,5]decatrienes and spiro[4,6]undecatrienes, as
well as the reduced bromophenyl oximinoamides) (Nicholas
et al., 2003). Common to all of the bromotyrosine-derived com-
pounds are a central amide group, an oxyimine to the carboxy
side of the amide, and polar substituents to the amino side of
the amide.
The assays performed on isolated compounds indicated that
a mixture of 1,3-pyridinium polymers derived from Amphimedon
sp. represented the most potent inhibitors of MCA, showing
submicromolar IC50 values of 0.1 mM. Furthermore, the glyco-
sphingolipid oceanapiside inhibitedMCA at lowmicromolar con-
centrations (IC50 10 mM for M. tuberculosis and 0.5 mM for1296 Chemistry & Biology 22, October 22, 2015 ª2015 Elsevier Ltd AM. smegmatis) (Nicholas et al., 2003). However, a completely
different class of compounds, the known sulfated terpenes suva-
nine and halisulfate, isolated from extracts of Coscinoderma
matthewsi, were only modest inhibitors of M. smegmatis MCA
with IC50 values of 60 and 40 mM, respectively (Nicholas et al.,
2003). The remaining three inhibitors were isolated from cultures
of terrestrial fungi. These included the known compounds glio-
toxin (IC50 50 mM for M. tuberculosis and 50 mM for
M. smegmatis), the analog S,S-dimethyl gliotoxin (IC50 70 mM
for M. tuberculosis), and the anthraquinone physcion (IC50
50 mM for M. smegmatis) (Nicholas et al., 2003).
The competition assays carried out to investigate the mode of
MCA inhibition showed that the two types of bromotyrosine-
derived natural products are competitive inhibitors ofMCA, while
oceanapiside (an a,o-bisaminohydroxy glycosphingolipid), and
the fungal metabolite gliotoxin (a dithiadiketopiperazine) are sim-
ple and mixed non-competitive inhibitors.
These results, therefore, demonstrate that bromotyrosine-
derived natural products combine only with the free enzyme,
while oceanapiside and gliotoxin can interact with various forms
of free or substrate-bound MCA (Nicholas et al., 2003). Since
bromotyrosine-derived natural products contain a centrally
located amide and compete directly with the substrate MsmB
for MCA activity, these compounds were thought to most likely
mimic the amide bond connecting cysteine and glucosamine in
mycothiol, which is cleaved by MCA (Figure 6). This notion was
confirmed by the fact that bromotyrosine-containing natural
products lacking an amide group were inactive in theMCA assayll rights reserved
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tigated compounds were not assessed. Furthermore, the
profiling of cellular biomarkers of enzyme activity in whole bacte-
rial cells or in animals was not performed.
Type II Fatty Acid Synthase Pathway:
b-Ketoacyl-ACP Synthase and NADH-Dependent
Enoyl-ACP Reductase InhA
Fatty acid synthase (FAS) is a multienzyme protein catalyzing
fatty acid (FA) synthesis. Many bacteria and plants possess a
dissociable FAS type II pathway (FAS-II), where each individual
reaction is catalyzed by a discrete monofunctional peptide. In
contrast, yeast and mammalian systems possess a multifunc-
tional FAS-I system (Slayden et al., 1996). FAs are essential for
all living organisms because of their key roles in membrane con-
struction and in energy production. M. tuberculosis employs
both FAS-I and FAS-II systems. FAS-I is responsible for the syn-
thesis of short-chain FAs, whereas the FAS-II system extends
these FAs for the synthesis of very long-chain mycolic acids.
These are important components of the mycobacterial cell wall
(Banerjee et al., 1994). The monofunctional mycobacterial poly-
peptide FAS-II system functions primarily as an elongating sys-
tem in mycobacteria (Bloch, 1977). The initial steps involved
within this synthase utilize palmitoyl-CoA:ACP (acyl-carrier-pro-
tein) transacylase, malonyl-CoA:ACP transacylase, and 3-ke-
toacyl-ACP synthetase. The subsequent steps involve the
reduction of the b-ketoester-ACP by an NADPH-dependent
b-ketoacyl-ACP reductase, followed by dehydration (b-hydrox-
yacyl-ACP dehydratase) to generate trans-2-unsaturated acyl-
ACP, which is then reduced by an NADH-dependent enoyl
reductase (InhA) to form the C18 ACP. This then serves as a sub-
strate for additional rounds of elongation (Bloch, 1977).
Thiolactomycin (TLM) (Figure 3) is a unique thiolactone antibi-
otic isolated initially from a soil organism, Nocardia sp. (Oishi
et al., 1982). This compound exhibits potent in vivo activity
against a broad spectrum of pathogens, including Gram-positive
cocci and enteric, acid-fast, and anaerobic bacteria (Noto et al.,
1982). It is a selective inhibitor of type II FA biosynthesis and
is also orally available and non-toxic in the mouse model (Al-
Balas et al., 2009; Kremer et al., 2000). Slayden et al. (1996)
evaluated thiolactomycin activity against M. tuberculosis and
M. smegmatis. The obtained MIC values in liquid media were
92.5 and 278 mM forM. tuberculosis andM. smegmatis, respec-
tively. Furthermore, the addition of TLM to macrophage cultures
containing M. tuberculosis resulted in bacterial killing in a dose-
dependent manner (Slayden et al., 1996).
The work of these researchers revealed that TLM induced the
strong inhibition of both FA (C18-C34) and mycolic acid synthe-
sis (amongwhich a-mycolates were almost completely inhibited,
whereas the a9-mycolates were only slightly inhibited, while the
synthesis of the epoxymycolates also appeared to be inhibited)
(Slayden et al., 1996). IC50 calculated on the basis of a dose-
response curve against the dissociated mycobacterial FAS-II
system was 23.17 mM. Slayden et al. (1996) proposed that the
FAS-II system was inhibited presumably through the effect on
the FAS-II b-ketoacyl-ACP synthase.
More recent research produced evidence that TLM targets
two b-ketoacyl-ACP synthases, KasA and KasB (Figure 4). This
notion is consistent with the fact that both enzymes belong toChemistry & Biologthe FAS-II system (Kremer et al., 2000). Overexpression studies
also provide indirect evidence that KasA and KasB are TLM tar-
gets. It is known that KasA may participate in the synthesis of
C18–C34 FAs, whereas KasB may be involved in the later steps
of mycolic acid biosynthesis. Subsequent MIC determinations
using a variety of agents that require penetration through the
mycobacterial cell wall (such as rifampicin and other well-char-
acterized mycolic acid inhibitors, including isoniazid), however,
infer that TLM sensitivity is not likely to be mediated by cell
wall permeability, and that its mechanism of action is dissimilar
to other known mycolic acid inhibitors (Kremer et al., 2000).
Slayden et al. (1996) also demonstrated that the multifunc-
tional mycobacterial FAS-I system was insensitive to TLM in
a dose-dependent manner at up to 27.8 mM. Their results
confirmed previous ones suggesting that TLM inhibits bacterial
and plant FAS-II, but not mammalian or yeast FAS-I (Hayashi
et al., 1983). Kremer et al. (2000) proposed that enzyme activity
was linked to whole-cell activity via the determination of
14C-labeled enzyme products (14C-labeled FA and mycolic
acid methyl esters registered on the autoradiograms) and deter-
mination of the wall fraction possessing mycolate-synthesizing
activity; however, the profiling of cellular biomarkers of enzyme
activity in animals was not performed.
Pyridomycin (Figure 3) is produced by Streptomyces pyrido-
myceticus (Maeda et al., 1953) or Dactylosporangium fulvum
(Shomura et al., 1986). By way of employing the resazurin reduc-
tion microplate assay, Hartkoorn et al. (2012) showed that pyri-
domycin is effective against all members of the Mycobacterium
genus tested, including M. tuberculosis (strain H37Rv; MIC
0.72 mM) andM. smegmatis (strain mc2 155; MIC 1.44 mM); how-
ever, there was no detectable activity against other bacteria,
including the close relative Corynebacterium glutamicum
(MIC >185 mM). These data confirm that pyridomycin acts
specifically against mycobacteria, with little or no activity against
other Gram-positive and Gram-negative species (Maeda et al.,
1953). Further investigation demonstrated that pyridomycin is
bactericidal against M. tuberculosis H37Rv at concentrations
of 1.15–2.31 mM, but has no activity against non-replicating
M. tuberculosis. This result suggests that it may target a function
involved in active growth (Hartkoorn et al., 2012).
Hartkoorn et al. (2012) also showed that the tested compound
was able to enter macrophages, and arrested bacterial replica-
tion in the ex vivo test after the infection of activated THP1-
derived macrophages. Furthermore, their work revealed that
pyridomycin has higher selectivity forM. tuberculosis compared
with the human cells tested. Their results demonstrated a selec-
tivity index >100-fold higher for M. tuberculosis than for HepG2
cells (human hepatic cell line) or A549 cells (human lung epithe-
lium cell line) (Hartkoorn et al., 2012).
The mechanism of action of pyridomycin is based on the
inhibition of mycolic acid synthesis in a concentration-depen-
dent manner in M. tuberculosis. Pyridomycin not only binds
to the NADH binding site, in NADH-dependent enoyl-ACP
reductase InhA (Figure 4), but also occupies part of the substrate
lipid site, which sets it apart from isoniazid (Hartkoorn et al.,
2012). Compared with isoniazid, pyridomycin activity also does
not need any intracellular activation step (it is not a prodrug).
However, isoniazid-resistant clinical isolates carrying the inhA
[c(15)t] promoter mutation displayed cross-resistance withy 22, October 22, 2015 ª2015 Elsevier Ltd All rights reserved 1297
Table 2. Compounds of Natural Origin Targeting Mycobacterial Enzymes
Compound Source Target MIC (mM) IC50 (mM) Reference
Lassomycin Lentzea kentuckyensis sp. ClpC1 0.42–1.57 Gavrish et al., 2014
Ecumicin Nonomuraea sp., strain MJM5123 ClpC1 0.13–0.3 Gao et al., 2015
Acyldepsipeptides Streptococcus hawaiiensis ClpP 31–65 Ollinger et al., 2012
Cyclomarin A Streptomyces sp. ClpC1 0.3–2.5 Schmitt et al., 2011
Aporphine alkaloids Ocotea macrophylla MurE ligase 14–125 57–75 Guzman et al., 2010
Kuwanol E Morus nigra PtpB 1.9–0.5 Mascarello et al., 2013
Brunsvicamide B Tychonema sp. PtpB 7.3 Mu¨ller et al., 2006
Brunsvicamide C Tychonema sp. PtpB 8.0 Mu¨ller et al., 2006
Bromotyrosine-derived
natural products
Oceanapia sp.
Amphimedon sp.
Coscinoderma matthewsi
Mycena sp.
MCA 0.1–70 Nicholas et al., 2003
Thiolactomycin Nocardia sp. b-ketoacyl-ACP synthase 92.5 23.17 Slayden et al., 1996
Pyridomycin Dactylosporangium fulvum InhA 0.72–1.44 Hartkoorn et al., 2012
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Reviewpyridomycin, whereas the more common katG (S315T) isoni-
azid-resistant mutants retained full sensitivity to pyridomycin
(Hartkoorn et al., 2012).
Hartkoorn et al. (2012) were also able to show that enzyme ac-
tivity was linked to the whole-cell activity, via the determination
of 14C-labeled enzyme products (14C-labeled mycolic acids
determined by radiometric thin-layer chromatography; IC50 =
2.78 mM). Of note, in their work the profiling of cellular biomarkers
of enzyme activity in animals was not performed. All compounds
of natural origin targeting mycobacterial enzymes are summa-
rized in Table 2.
Concluding Remarks
Compounds isolated from bacteria, fungi, plants, and marine
invertebrates are still a valuable source or potential source of
new inhibitors of mycobacterial enzymes. The important criteria
during the in vitro activity screening tests are bacteria growth
and assay conditions. Of note, these should be physiologically
relevant. Furthermore, the activity of tested compounds may
depend on anaerobic/aerobic conditions and nutrient condi-
tions. In addition, because the unique mycobacterial cell wall
limits the entry of potential active compounds into the cell, there
is a strong need to perform whole-cell inhibition assays, which
must be linked with the activity of the investigated enzyme.
Only animal models allow the verification of the suitability of
the compound regarding the pharmacokinetic parameters.
Moreover, it must be recalled that the high lipophilicity of some
of the most active compounds reduces potential oral availability,
and suggests the necessity for chemical modifications of the
investigated structure, hence leading to the improvement of its
pharmacokinetic parameters.
The tests performed while investigating compounds
described in this work meet the criteria mentioned above only
for Clp inhibitors and FAS-II inhibitors. These natural products
have been very well researched and their molecular interactions
with enzymes are well studied. The most promising candidates
for drug leads are Clp inhibitors, and Clp is a valid drug target
against M. tuberculosis. ClpP inhibitors (ADEPs) were discov-
ered in 2005, and the latest work from 2015 (ecumicin) shows1298 Chemistry & Biology 22, October 22, 2015 ª2015 Elsevier Ltd Athat soil microorganisms are good source for new antibiotics
and that the high-throughput screening method is very efficient.
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